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PAO5
AN ECONOMIC MODEL FOR
GASTROINTESTINAL RISK STRATIFICATION
COMPARING COX-2 INHIBITORS TO
TRADITIONAL NSAIDS FOR ARTHRITIS
TREATMENT
DeLattre ML1, Schaefer MG2, Morreale AP2, Plowman BK2
1VA San Diego Healthcare System/ University of the Paciﬁc,
San Diego, CA, USA; 2VA San Diego Healthcare System, San
Diego, CA, USA
The cost-effectiveness of cyclooxygenase-2 (COX-2)
inhibitors over traditional non-steroidal anti-
inﬂammatory drugs (NSAIDs) has not been demonstrated
in the general population. There is signiﬁcant evidence 
to support that risk factors such as age, gastrointestinal
event history and NSAID intolerance alone or in combi-
nation can increase the rate of clinically signiﬁcant upper
gastrointestinal events (CSUGIE).
OBJECTIVES: This pharmacoeconomic model compares
the cost-effectiveness proﬁles of NSAIDs, rofecoxib and
celecoxib therapies in populations at high risk of CSUGIE
from the perspective of Veteran Affairs (VA) Healthcare
System.
METHODS: Data was reviewed from published post-
marketing outcome trials and FDA reviews of rofecoxib
and celecoxib compared to naproxen, ibuprofen, and
diclofenac and incorporated into an event targeted one-
year decision model. Gastrointestinal (GI) event rates
were stratiﬁed by high-risk subgroups receiving chronic
treatment for arthritic conditions. Additionally, dyspep-
sia, renal toxicity, and cardiovascular adverse event rates
were included to capture a comprehensive representation
of safety for all agents compared. Sensitivity analysis was
performed on all major indices based on variations in
results found in reviewed studies.
RESULTS: In spite of the substantial differences in GI
event rates for the following high-risk subgroups of 
age ((NSAIDS: 8.63–12.7%, celecoxib and rofecoxib:
3.54–7.9%), history of CSUGIE (NSAIDS: 11.8–15.3%,
celecoxib 7.8%, rofecoxib 6.72%) and previous NSAID
intolerance (NSAIDS: 3.89–7.8%, celecoxib 8.0%, 
rofecoxib1.87%), NSAIDs remain more cost-effective. In
non-aspirin patients, inclusion of myocardial infarction
(MI) event rates (NSAIDS: 0.15%, celecoxib 0.53%, rofe-
coxib 0.74%) resulted in higher cost for patients receiv-
ing rofecoxib. The primary cost drivers identiﬁed were
CSUGIEs, hospitalizations, and differences in cardiovas-
cular toxicity, speciﬁcally rates of congestive heart failure
and MI.
CONCLUSIONS: Inclusion of overall safety data in high-
risk populations did not alter the cost effectiveness of
NSAIDs compared to COX-2 inhibitors as the primary
therapy in treatment of arthritis patients in the VA
Healthcare System.
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COST-EFFECTIVENESS OF BISPHOSPHONATE
THERAPIES IN POST-MENOPAUSAL WOMEN:A
THRESHOLD ANALYSIS
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Osteoporosis is a large and growing disease category with
signiﬁcant health consequences. Information on the cost-
effectiveness of preventing and treating this disease may
help healthcare payers allocate resources more efﬁciently.
OBJECTIVE: To assess cost-effectiveness of bisphospho-
nate therapies in multiple populations, subject to a value
threshold.
METHODS: A fracture incidence-based Markov model
of osteoporosis, where patients transition across outcome
states over time (e.g., fracture, healthy, dead), was used
to estimate incremental cost per QALY gained ratios. The
base case analysis was conducted on a cohort of women
aged 65 years with low bone mineral density (BMD) 
and prevalent vertebral fracture, with 3 years of treatment
with Actonel or Fosamax, using a 3-year time horizon.
Model inputs included fracture incidence rates, relative
risk (RR) reduction of fracture due to risk factors, frac-
ture costs, prices/day (Actonel $1.95; Fosamax $2.21),
health utilities, and efﬁcacy in terms of relative risk (RR)
of fracture reductions for hip (60% Actonel; 51%
Fosamax) and vertebral (49% Actonel; 47% Fosamax).
A 3% discount rate was applied to costs and outcomes.
Multiple populations were evaluated by varying efﬁcacy
rates (upper/lower 95% conﬁdence intervals), fracture
costs (+/-25%), utility values (+/-50%), fracture RR
(2.0–7.0), age (55–75), therapy discontinuation (0%–
76%), and time horizon (to lifetime).
RESULTS: Using a $30,000 per QALY gained cost-
effectiveness threshold, Actonel compared to no treat-
ment was cost-effective in the majority of populations.
Under base case assumptions Actonel’s cost/QALY gained
was $16,158 and dominated Fosamax (i.e., less costly
and more effective). Actonel’s cost/QALY ratio crossed
the threshold as RR of fracture declined (<5), starting
cohort age fell (<62), discontinuation rose, fracture costs
decreased (>25%), or fracture-related utility decrements
decreased (>50%).
CONCLUSIONS: Many high-risk patient subpopula-
tions can be treated economically with bisphophonates.
The most signiﬁcant drivers are RR of fracture, starting
cohort age and time horizon.
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OBJECTIVE: Miacalcin is a recently (2000) introduced
anti-osteoporosis drug. Clinical trials have demonstrated
that the drug appears to be relatively free of side-effects.
This preliminary analysis investigates the relationship
between the consumption of Miacalcin and other health
care costs.
METHODS: All physician service and medication claims
submitted to the government of the province of Québec,
Canada, were obtained for individuals with at least one
prescription of Miacalcin or another anti-osteoporosis
drug (Evista or Fosamax), during the period January 
1, 1999 to March 31, 2001. Two-part models (multiple
logistic regression followed by linear regression) were
used to analyze the data.
RESULTS: Based on utilization records of 60,469 
individuals (for all anti-osteoporosis drugs combined),
increased use of Miacalcin appears associated with a
small reduction in the number of subsequent diagnostic
tests and prescriptions for other drugs: 100 days over 
the ﬁrst 6 months of 2000, translating into reductions of
about 0.3 tests over the next 9 months, or about $24; and
a reduction in the number of prescriptions for other drugs
in the subsequent 9 months of about 3.1, or about $84.
Consumption of Miacalcin does not, however, appear 
to be associated with a subsequent overall reduction in
physician service costs. People who were prescribed 
Miacalcin in 2000 had higher physician costs in 1999
than people who consumed either of the two other drugs
in 2000.
CONCLUSIONS: Evidence that people who were pre-
scribed Miacalcin differ systematically from those who
were prescribed other anti-osteoporosis drugs may limit
generalizability of the ﬁndings. Unit costs used were
somewhat imprecise. Nonetheless, the cost of Miacalcin
appears to be partially offset by subsequent savings in
other health care costs, primarily medication costs.
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FIRST-YEAR COSTS ASSOCIATED WITH NOVEL
DISEASE-MODIFYING DRUGS IN THE
TREATMENT OF PATIENTS WITH RHEUMATOID
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Huse D1, Doyle J2
1PharMetrics, Inc, Watertown, MA, USA; 2Aventis
Pharmaceuticals, Parsippany, NJ, USA
OBJECTIVE: To identify differences in rheumatoid
arthritis care costs and utilization among patients who
initiate therapy with leﬂunomide (LEF), etanercept (ETA),
or inﬂiximab (INF).
METHODS: A retrospective cohort analysis of patients
diagnosed with rheumatoid arthritis (RA) and starting
treatment with LEF, ETA, or INF was used. Data for this
study were obtained from the PharMetrics Integrated
Outcomes Database, comprised of claims paid by health
plans to providers of medical and pharmacy services.
Patients were selected who were diagnosed with RA (ICD
9 code 714), received LEF, ETA, or INF in 1999 and did
not previously receive any of these agents. Eligible
patients also were required to have complete data for 12
months before and after they started therapy with a study
drug. Payments for RA-related services during the 12-
month baseline and follow-up periods were compared
between cohorts using Wilcoxon’s rank sum test.
RESULTS: A total of 627 LEF- and 466 ETA-treated RA
patients were identiﬁed. No INF-treated patients met the
selection criteria. During the baseline period, mean
annual payments for RA-related services were higher 
in the ETA versus the LEF cohort ($2,567 vs. $1,944; 
P < 0.0001). In the follow-up period, mean annual RA-
related costs increased to $12,344 in the ETA cohort
versus $4,754 in the LEF cohort (P < 0.0001). Most of
this difference was in pharmacy costs ($10,423 in ETA
vs. $3,217 in LEF), while other direct medical costs were
similar between cohorts ($1,921 in ETA vs. $1,537 in
LEF).
CONCLUSIONS: Compared with patients in the ETA
cohort, health insurance payments for LEF-treated
patients were signiﬁcantly lower during the 12 months
following the initiation of therapy. This difference in
mean RA-related charges was attributable mainly to the
difference in arthritis-related pharmacy charges, and far
exceeded pre-existing cost differences among the cohorts.
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AN ECONOMIC COMPARISON BETWEEN COX-
2 INHIBITORS AND CONVENTIONAL NSAIDS
IN THE TREATMENT PAIN RELATED TO
ARTHRITIS
Beard S, Gaffney L
RTI Health Solutions, Manchester, UK
OBJECTIVE: Selective COX-2 inhibitors (coxibs)
provide comparable efﬁcacy with less gastrointestinal
(GI) adverse events compared to the conventional non-
selective non-steroid anti-inﬂammatory drugs (NSAIDs)
in patients with arthritis. We conducted an economic
analysis, focusing speciﬁcally on differences in GI-related
event rates between the coxibs and conventional NSAIDs.
METHODS: We developed a decision model, using
Microsoft Excel® and Decisioneering Crystal Ball®, which
focused on three areas of potential economic differen-
tiation between treatment with COX-2 inhibitors and 
conventional non-selective NSAIDs; GI-related complica-
tions, uncomplicated GI ulcers, and GI-related adverse
effects. The model was populated with published data
describing resource implications and mortality risks, unit
costs, underlying NSAID GI-event risks and relative GI-
event risks for coxibs. We considered two treatment
options (i) celecoxib and (ii) a single NSAID drug based
on naproxen, ibuprofen, or diclofenac (as observed in the
CLASS study). Sensitivity analyses considered variation 
in the underlying GI-event risks alongside general uncer-
tainty in resource usage and drug cost data.
